摘要
目的:评价脐带间充质干细胞(hUC-MSC)联合单倍体造血干细胞移植(Haplo-HSCT)治疗重型再生障碍性贫血-Ⅱ型(SAA-Ⅱ)的疗效和安全性。方法:回顾性分析11例接受Haplo-HSCT联合hUC-MSC治疗的SAA-Ⅱ患者的临床资料,观察移植后造血重建及移植相关并发症。结果:11例患者移植后均获得快速造血重建,中性粒细胞>0.5×109/L和血小板>20×109/L的中位植入时间分别为13(9~17)d和17(11~30)d。6例发生急性移植物抗宿主病,Ⅱ~Ⅳ度急性移植物抗宿主病发生率36.4%;3例发生慢性移植物抗宿主病,发生率27.3%。中位随访20(10~94)个月,11例患者中9例生存,总生存率81.8%。结论:亲缘Haplo-HSCT联合hUC-MSC输注治疗SAA-Ⅱ是安全、有效的,移植后造血重建快,移植物抗宿主病和感染是主要并发症。
Objective：To evaluate the safety and efficacy of human umbilical cord-derived mesenchymal stem cells（hUC-MSC）combined with haploidentical hematopietic cell transplantation（Haplo-HSCT）in the treatment of severe aplastic anemia-Ⅱ（SAA-Ⅱ）.Method：Eleven patients with SAA-Ⅱ received Haplo-HSCT with hUCMSC,and the hematopoietic recovery and transplant-associated complications were monitored.Result：All the patients achieved rapid hematopoietic reconstruction after HSCT.The average time of neutrophils count〉0.5×109/L and PLT〉20×109/L were 13（9 to 17）days and 17（11 to 30）days,respectively.Six patients developed acute graft versus host disease and the incidence ofⅡ to Ⅳ grade was 36.4%.Three patients developed chronic graft versus host disease and the incidence was 27.3%.The median follow-up time was 20（10 to 94）months,9 patients survived and 3-years overall survival rate was 81.8%.Conclusion：Haplo-HSCT combined with hUC-MSC infusion is a safe and effective approach to cure SAA-Ⅱ.The hematopoietic reconstitution is rapid after transplantation,and graft versus host disease and infection are major complications.
作者
宋晓晨
周芳
宋宁霞
刘希民
解琳娜
余喆
SONG Xiaochen;ZHOU Fang;SONG Ningxia;LIU Ximin;XIE Linna;YU Zhe(Departement of Hematology, General Hospital of Jinan Military Area,Jinan, 250031, China)
出处
《临床血液学杂志》
CAS
2018年第3期369-372,共4页
Journal of Clinical Hematology
关键词
重型再生障碍性贫血
造血干细胞移植
单倍性
间充质干细胞
severe aplastic anemia
hematopoietic stem cell transplantation
haploidentical
mesenchymal stem cells
